• Scenario-Driven Solutions with JNK-IN-7 in Apoptosis Assays

  2026-05-09

  This article uses five real laboratory scenarios to illustrate how JNK-IN-7 (SKU A3519) delivers reproducible, data-backed results in cell viability and apoptosis assays. Learn why researchers trust this selective JNK inhibitor for MAPK pathway studies, with evidence-based guidance and direct comparison to alternatives.

• Applied Workflows with Protoporphyrin IX: Photodynamic Compo

  2026-05-09

  Protoporphyrin IX is not just a heme biosynthetic intermediate—it is a cornerstone for advanced photodynamic cancer diagnosis and ferroptosis research. Discover evidence-backed, stepwise protocols, troubleshooting tips, and the latest innovations, including practical translation from the METTL16-SENP3-LTF axis study, to optimize your experimental outcomes with APExBIO’s high-purity reagent.

• Macrophage M1 Polarization via TLR4 in Colitis-Linked Cancer

  2026-05-08

  Liu et al. reveal that Jiedu Xiaozheng Yin (JXY) suppresses colitis-associated colorectal cancer progression by promoting macrophage polarization toward the anti-tumorigenic M1 phenotype through the TLR4 pathway. This work highlights the relevance of immune microenvironment modulation for chemopreventive strategies and provides data-driven insight into pathway-specific interventions.

• Rapid Purification of Recombinant Annexin V for Biophysical

  2026-05-07

  This study introduces a streamlined, calcium-dependent method for purifying recombinant annexin V to high purity, enabling advanced biophysical analyses. The protocol overcomes major contamination issues seen in bacterial expression systems and supports applications such as ion channel characterization and structural biology.

• HyperFluor™ 488 Goat Anti-Rabbit IgG: Protocol and Best Use

  2026-05-07

  HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody provides reliable fluorescent detection of rabbit primary antibodies in immunofluorescence, flow cytometry, and microscopy. It should not be used with non-rabbit primary antibodies or in direct-detection workflows. This article offers actionable, evidence-based guidance for optimal use in fluorescence-based assays.

• Neuronal Glycogen Breakdown Reduces Tauopathy via PPP-Mediat

  2026-05-06

  This study reveals that neuronal glycogen accumulation exacerbates tauopathies such as Alzheimer’s disease by impairing glucose metabolism and oxidative stress management. Enhancing glycogen breakdown mitigates tau pathology by redirecting glucose flux to the pentose phosphate pathway, highlighting a novel therapeutic angle for neurodegenerative conditions.

• ABT-888 (Veliparib) for Potent DNA Repair Inhibition in Canc

  2026-05-06

  Harness the power of ABT-888 (Veliparib) as a highly selective PARP1/2 inhibitor to sensitize tumor cells in colorectal and microsatellite instability (MSI) models. This guide delivers advanced workflow strategies, troubleshooting tips, and direct translation of breakthrough reference findings to experimental design.

• SGI-1027: Strategic Advances in Cancer Epigenetic Modulation

  2026-05-05

  This thought-leadership article explores the mechanistic and translational significance of SGI-1027, a potent DNA methyltransferase inhibitor, in redefining cancer epigenetics. Integrating recent in vitro methodologies, competitive positioning, and actionable protocol guidance, it offers translational researchers a roadmap to maximize the impact of epigenetic modulation in oncology. The piece uniquely bridges mechanistic insight with experimental strategy, expanding the discussion beyond standard product summaries and supporting future-oriented translational research.

• Inducing Mammalian Embryonic Dormancy via mTOR Inhibition In

  2026-05-05

  This protocol-focused study presents a noninvasive, scalable method to induce a reversible dormant state in mammalian embryos and pluripotent stem cells through pharmacological mTOR inhibition. The approach enables detailed investigation of embryonic dormancy mechanisms and offers significant advantages over traditional, invasive models, opening new possibilities for developmental biology and assisted reproduction research.

• NBC19 (SKU BA6129): Reliable NLRP3 Inflammasome Inhibition

  2026-05-04

  NBC19 (SKU BA6129) is a nanomolar-potency NLRP3 inflammasome inhibitor engineered for reproducibility in inflammation research. This article addresses common laboratory challenges in IL-1β release assays, outlining how NBC19 enables precise modulation of inflammasome activation. Data-backed comparisons and workflow guidance position NBC19 as a dependable tool for bench scientists seeking confidence in their cytokine and cell viability studies.

• Chlorpromazine HCl as a Precision Tool for Endocytosis Resea

  2026-05-04

  Explore how Chlorpromazine HCl, a powerful dopamine receptor antagonist, advances cell biology and neuropharmacology by enabling precise modulation of endocytic pathways. This article provides a rigorous, application-focused analysis distinct from existing overviews.

• IGF2BP3–FZD1/7 Axis Drives Carboplatin Resistance in TNBC CS

  2026-05-03

  This study uncovers how IGF2BP3 stabilizes FZD1/7 mRNAs to enhance stem-like properties and carboplatin resistance in triple-negative breast cancer (TNBC) cancer stem cells. Targeting this axis, especially in combination with platinum-based DNA synthesis inhibitors, may overcome chemoresistance and enable more effective preclinical oncology research.

• Chlorpromazine HCl: Mechanistic Insights for Translational I

  2026-05-02

  This thought-leadership article explores Chlorpromazine HCl’s evolution from cornerstone antipsychotic to a versatile research tool at the intersection of neuropharmacology and host-directed anti-infective strategies. By integrating mechanistic evidence, protocol guidance, and translational context, it offers strategic recommendations for researchers aiming to accelerate discovery and innovation.

• U-73122: Precision Phospholipase C Inhibitor for Cell Signal

  2026-05-02

  U-73122 is a benchmark phospholipase C inhibitor enabling precise dissection of PLC-mediated calcium flux and chemotaxis in cancer and inflammation models. Its selectivity and well-characterized performance make it indispensable for reproducible studies, as demonstrated in advanced breast cancer invasiveness research.

• Plk1 Regulation of p31comet: Control of Mitotic Checkpoint D

  2026-05-01

  This study uncovers how Polo-like kinase 1 (Plk1) phosphorylates p31comet at S102, suppressing its ability to promote the disassembly of the mitotic checkpoint complex (MCC) via TRIP13. These findings clarify a key regulatory step in mitotic checkpoint inactivation, with implications for cell cycle control and cancer research.

15613 records 1/1041 page Next 12345 下5页 Last page